This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biosimilars In Emerging Economies - Advanced Recombinant Technology Platforms And Low Cost Manufacturing Put India And China At A Strategic Advantage In Biosimilar Production

Figure 3: Biosimilars in Emerging Economies, INF Alpha Biosimilars Marketed Outside the US and EU, 2011 14

Figure 4: Biosimilars in Emerging Economies, Biosimilars Comparison With Biologics and Generic, 2012 16

Figure 5: Biosimilars in Emerging Economies, Size and Complexity, Small Molecule Drugs and Proteins, 2012 17

Figure 6: Biosimilars in Emerging Economies, Cost and Timeline for Biosimilar Development, 2011 18

Figure 7: Biosimilars in Emerging Economies, Biosimilars Development, 2011 19

Figure 8: Biosimilars in Emerging Economies, Drivers and Barriers, 2011 20

Figure 9: Biosimilars in Emerging Economies, Top 10 Biologics, 2011 22

Figure 10: Biosimilars in Emerging Economies, Revenue Forecasts ($bn), 2002–2018 24

Figure 11: Biosimilars in Emerging Economies, India, Revenue Forecasts ($bn), 2002–2018 28

Figure 12: Biosimilars in Emerging Economies, DRL, SWOT Analysis, 2012 32

Figure 13: Biosimilars in Emerging Economies, Biocon, SWOT Analysis, 2012 33

Figure 14: Biosimilars in Emerging Economies, IBPL, SWOT Analysis, 2012 35

Figure 15: Biosimilars in Emerging Economies, Reliance Life Sciences, SWOT Analysis, 2012 37

Figure 16: Biosimilars in Emerging Economies, Wockhardt, SWOT Analysis, 2012 38

Figure 17: Biosimilars in Emerging Economies, Lupin, SWOT Analysis, 2012 39

Figure 18: Biosimilars in Emerging Economies, Cipla, SWOT Analysis, 2012 40

Figure 19: Biosimilars in Emerging Economies, China, Revenue Forecasts ($bn), 2002–2018 41

Figure 20: Biosimilars in Emerging Economies, 3SBio, SWOT Analysis, 2012 44

Figure 21: Biosimilars in Emerging Economies, CPGJ, SWOT Analysis, 2012 46

Figure 22: Biosimilars in Emerging Economies, Biotech Pharma, SWOT Analysis, 2012 47

Figure 23: Biosimilars in Emerging Economies, Steps of Risk Management, Turkey, 2012 51

Figure 24: Biosimilars in Emerging Economies, R&D Pipeline by Phase (%), 2011 58

Figure 25: Biosimilars in Emerging Economies, R&D Pipeline by Therapy Class (%), 2011 59

Figure 26: Biosimilars in Emerging Economies, Strategies Adopted By Branded Biologic Companies to Beat Generic Competition, 2011 69

7 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs